Clinical Data

obesity overweight weight loss weigh
Biotech

Lilly's obesity triple threat tops phase 3 efficacy forecasts

Lilly linked its triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee osteoarthritis.
Nick Paul Taylor Dec 11, 2025 8:15am
Lung

GRI touts IPF safety edge, lung function gains amid cash crunch

Dec 11, 2025 5:12am
An arrow incrementally going up stairs before pointing straight up Blue background

Roche links SERD to 30% breast cancer risk reduction in phase 3

Dec 10, 2025 8:15am
Basketball players hands reaching for a ball near the hoop during a professional game

Exicure scores in phase 2 multiple myeloma program

Dec 9, 2025 10:15am
weight loss drugs obesity

Wave, Structure stocks double on obesity data readouts

Dec 8, 2025 10:50am
Abstract arrangement of geometric shapes including spheres a pyramid and balancing wooden and stone slabs

BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial

Dec 8, 2025 7:47am